|
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer, central nervous system (CNS) disorders and other unmet medical needs. Our motto, "Saving Lives Through Innovation," represents the Company's
use of scientific innovation to improve the health and wellness of patients. We develop therapies that treat specific disease states, while minimizing side effects in order to help patients regain quality of life during treatment.
Rexahn currently has three clinical stage drug candidates: ArchexinTM, SerdaxinTM and ZoraxelTM. The Company's lead cancer candidate, Archexin (formerly named RX-0201), is currently in Phase II clinical trials for patients with pancreatic cancer and renal cell carcinoma (RCC),
an abnormal growth of cells lining the tubules of the kidney. Multiple indications are possible. Rexahn is also developing SerdaxinTM for treatment of depression, anxiety and neurodegenerative disorders. Serdaxin Phase II clinical trials are ongoing in 2009 for major depressive disorder. SerdaxinTM increases availability of neurotransmitters, serotonin and dopamine, with mechanisms different from the current market leaders of reuptake inhibitors such as SSRIs and SNRIs. For sexual dysfunction, ZoraxelTM isin Phase II clinical trials for patients with erectile dysfunction (ED). ZoraxelTM is the first centrally acting dual enhancer of serotonin and dopamine, affecting all three phases of sexual function, such as sexual arousal, erection and release.
Further, Rexahn leverages proprietary nanomedicine research and multi-target aimed ligands platform to strengthen its preclinical pipeline, and develop cancer drugs that offer greater therapeutic benefits and quality of life for patients. Rexahn is based in Rockville, Maryland and is currently traded on the NYSE Amex under the symbol RNN.
|
